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Abstract
Introduction: Familial hypercholesterolaemia (FH) is a clinical syndrome
characterised by elevated serum total cholesterol (TCHOL) levels due to an
increase in low-density lipoprotein (LDL) cholesterol, by tendon xanthomata and
clinical manifestations of ischaemic heart disease in early life. Typically, it results
from mutations in the low-density lipoprotein receptor (LDLR) gene. So far, more
than 800 mutations have been reported for the LDLR gene and account for FH.
The nature of LDLR gene mutations varies among different ethnicities. Until now
no mutations of LDLR have been reported in the Albanian population.
Material and methods: We assessed the contribution of the LDLR gene mutations
as causes of FH in an Albanian population. Fifty probands with a clinical
diagnosis of FH were included. We analysed all the exons and the promoter of
the LDLR gene by using restriction isotyping or direct sequencing.
Results: Twenty-one patients were heterozygous for the 1646G>A mutation (FH
Genoa) in exon 11 and 9 patients were heterozygous for the 81T>C mutation in
exon 2 of the LDLR gene.
Conclusions: This report describes two LDLR gene mutations accounting for FH
in Albania (1646G>A, 81T>C). 
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Introduction
The low-density lipoprotein receptor (LDLR; MIM# 143890) is a 160 kD,
cell surface transmembrane protein that facilitates the uptake of plasma
LDL primarily into hepatocytes, where it is further catabolised [1]. A genetic
defect caused by mutations in the LDLR gene on chromosome 19 results
in malfunctioning or insufficient numbers of LDLR molecules, which
accounts for the reduced clearance of LDL molecules from the plasma via
the receptor-mediated pathway. Low-density lipoprotein is then catabolised
via a non-receptor mediated pathway. This abnormality leads to premature
development of atherosclerosis. The worldwide heterozygote frequency
for FH is about 1/500. The prevalence of homozygosity is much less, about
1/1000,000. The most common clinical features of FH are tendon
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xanthomata, xanthelasma palpebrarum, corneal
arcus and ischaemic heart disease. The clinical
diagnosis is only confirmed by identification of the
mutation in the LDLR  gene. However, to our
knowledge no mutation has been reported in the
Albanian population until now. Knowledge of the
mutations in the LDLR gene helps to confirm the
clinical diagnosis and also to identify younger
affected members in a known FH family.
Furthermore, presymptomatic diagnosis and early
therapeutic intervention could prevent premature
atherosclerosis. Thus, we undertook the present
study to characterise the mutations of the LDLR
gene in Albanian pedigrees with a clinical diagnosis
for heterozygous FH.
Material and methods
Patient recruitment
A total of 50 unrelated patients (33 males and 17
females) aged from 11 to 70 years old attending the
lipid clinic of the University Hospital Centre “Mother
Teresa” with a clinical diagnosis of heterozygous FH
participated in the study. The diagnosis of FH was
based on William’s clinical criteria [2]. In detail,
patients with plasma LDL-C levels above 190 mg/dl
and with a family history of tendon xanthomata were
considered as FH patients and were recruited into
our study. Hypercholesterolaemic patients with the
apo  lipoprotein (apo) B3500 gene mutation were
excluded by sequencing of the apo B gene and other
secondary causes of hypercholesterolaemia were
excluded by history, physical examination and the
appropriate laboratory tests including thyroid function
(TSH), creatinine, proteinuria and alkaline pho  -
sphatase.
Detection of low-density lipoprotein receptor 
gene mutations
In all cases, DNA analysis for the LDLR gene
was performed. Whole blood was collected from
all patients after informed consent. DNA was
extracted from the whole blood specimens as
described previously [3]. PCR was carried out
using 50 ng DNA isolated from each individual.
All LDLR gene exons and the promoter were
amplified as described previously [4]. PCR was
carried out using an MJR PTC-100 thermal cycler.
Restriction enzyme isotyping was first used for
detecting previously described LDLR gene
mutations in northwestern Greece, an area which
is next to Albania [5, 6]. Automated sequencing
was performed using the Applied Biosystems “Big
Dye Terminator Cycle Sequencing Ready Reaction
Kit” as instructed by the manufacturer (Applied
Biosystems). Both forward and reverse
sequencing were performed to confirm our
findings. The sequenced products were then
separated by capillary electrophoresis using an
ABI PRISM 3130 Genetic Analyzer. Sequencing
Analysis and Sequence Navigator software were
used to analyse the collected data and compare
them with the published reference sequence of
the LDLR gene. 
Results
This study led to the identification of 2 LDLR
gene mutations, which to our knowledge are the
first described in the Albanian population. Twenty-
one patients were heterozygous for the 1646G>A
mutation (FH Genoa) in exon 11 and 9 patients were
heterozygous for the 81T>C mutation in exon 2. No
patient was found to be homozygous for the above
2 mutations. The frequency of the above mutations
is shown in Table I, and the lipid profile of the
patients carrying the same mutation is shown in
Table II. There were no significant differences in the
values of serum lipid parameters or in the
prevalence of tendinous xanthomas, xanthelasma
palpebrarum, corneal arcus and ischaemic heart
disease among heterozygous patients carrying
these 2 LDLR gene mutations. 
Exon Nucleotide Amino acid Number ofP ercentage Detection 
change change patients of study group assay
2 81T>C C5W 9 18% Direct sequencing
11 1646G>A G528D 21 42% Direct sequencing
Table I. LDLR gene mutations found in Albanian pedigrees (n = 50)
Mutation  Age*T otal cholesterol** Triglycerides** HDL** cholesterol  LDL** cholesterol
81T>C 41 ±11 358 ±48 130 ±27 54 ±12 282 ±38
1646G>A 43 ±12 362 ±75 128 ±48 56 ±15 280 ±49
Table II. Lipid profile of the study population
*years, **mean value ±SD [mg/dl]
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Discussion
We undertook the present study to characterise
the mutations in the LDLR gene in Albanian
pedigrees with heterozygous FH. Forty-two percent
of the patients possessed the 1646G>A LDLR gene
mutation, located in exon 11. The LDLR activity is
known to be reduced to 2%. The same mutation
has previously been described in an Italian FH
family [7] and in Greek FH patients [5, 6]. The 81T>G
LDLR (5C>W) gene mutation, located in exon 2, has
a frequency of 18% in the Albanian population. The
activity of the LDLR resulting from the 81T>G
mutation is reported to be reduced to 5-15%. The
mutation was first described in Americans [8] 
and also in Croatian and English FH patients
[Database of LDLR  gene mutations in FH:
http://www.ucl.ac.uk/fh]. Furthermore, the mutation
81T>G has also been previously described in the
population of northwestern Greece [9].
Although the clinical criteria for the diagnosis of
heterozygous FH were met in all participants, not
all of the participants were genetically diagnosed
as FH heterozygotes. This finding can be explained
by the fact that we did not check for other genetic
syndromes that mimic FH such as familial
hypercholesterolaemia type III and autosomal
recessive hypercholesterolaemia.
The identification of these gene mutations will
improve genetic diagnosis of FH in the Albanian
population. From a public health point of view, the
knowledge of these mutations and their
distribution may favour the development of tailed
information and screening programmes based on
these data [10]. The improvement of genetic
diagnosis is of paramount importance for the early
diagnosis of new members of an affected family
or new probands in Albania. Therapeutic
intervention at this early stage is effective for the
primary prevention of coronary artery disease.
Combination therapy with a statin and ezetimibe
is now available for more plasma LDL-C reductions
[11]. Furthermore, the fact that gene therapy is not
far away makes the knowledge of the pathogenic
mutations in various populations of paramount
importance.
In conclusion, to our knowledge, this study
describes for the first time details of the LDLR gene
mutations causing FH in an Albanian population.
However, this is a preliminary publication and more
research is needed for the Albanian FH data to be
extended and effective in preventing cardiovascular
disease.
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